Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03934450 · ClinicalTrials.gov registry record · Phase 1
Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers Receiving a Seven Day Dose Regimen
A Phase 1 study, sponsored by University of Mississippi, Oxford.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03934450 is a Phase 1 study that has completed, run by University of Mississippi, Oxford. The registered enrollment target is 36 participants.
The verdict
NCT03934450, a Phase 1 study, has completed, sponsored by University of Mississippi, Oxford.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
To investigate the comparative tolerability, metabolism and pharmacokinetics of individual enantiomers of PQ in healthy human volunteers, receiving study drug over the course of 7 days.
Interventions
- DRUG Placebo
- DRUG RPQ
- DRUG SPQ
- DRUG Primaquine Phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-08-17 |
| Est. Completion | 2019-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03934450
The ClinicalTrials.gov registry entry for NCT03934450 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Mississippi, Oxford, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03934450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03934450 about?
NCT03934450 is a clinical study titled "Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers Receiving a Seven Day Dose Regimen". To investigate the comparative tolerability, metabolism and pharmacokinetics of individual enantiomers of PQ in healthy human volunteers, receiving study drug over the course of 7 days.
What is the current status of trial NCT03934450?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2018-08-17. Estimated completion is 2019-05-01.
What interventions are being tested in trial NCT03934450?
The interventions under investigation include: Placebo (DRUG), RPQ (DRUG), SPQ (DRUG), Primaquine Phosphate (DRUG).
Who is sponsoring clinical trial NCT03934450?
This trial is sponsored by University of Mississippi, Oxford, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.